Financial SupportThe recent grant from the Gates foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.
Market PotentialOvaprene is considered an exciting opportunity as it could be a blockbuster contraceptive device given the lack of convenient non-hormonal products on the market.
Regulatory ProgressDare finalizes Phase 3 plan for sildenafil cream for treating FSAD with the FDA, aligning over the study design, endpoints, and patient population.